Takeda、創薬初期プロセスの自動化に向けてInsilicoに6億ドルを投じる
Takedaはターゲット探索を目的に、Insilico Medicineと6億ドルの契約を結び、同社のPharma.AIプラットフォームへのアクセスを確保した。製薬大手がリスクの高い初期段階のR&DをAI専門企業にアウトソーシングする転換を示している。
takeda entered a strategic collaboration with insilico medicine, potentially worth $600m, to deploy ai in identifying new drug targets and small molecule generation. the agreement leverages insilico's pharma.ai suite, specifically its generative biology and chemistry tools, to de-risk takeda's discovery pipeline. the partnership highlights a trend where large pharmaceutical firms outsource the most speculative part of r&d to specialized ai vendors rather than building internal tech. successful execution here could force competitors to abandon internal platform development in favor of similar outsourcing models.